Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Journal of Medical Sciences
Year: 2001  |  Volume: 1  |  Issue: 6  |  Page No.: 393 - 395

Subacute Toxicity Studies of 4-hydroxy Nitrobenzene Isolated from Streptomyces Species

Zakia Sultana Sathi, A. S. M. Anisuzzaman, Golam Sadik and M. A. Gafur    

Abstract: The subacute toxicity study of an antimicrobial compound, 4-hydroxy nitrobenzene isolated from a Streptomyces species was carried out on long Evan’s rats. The compound, 4-hydroxy nitrobenzene (300μg) was administered daily for 14 days and its effect on body weight, hematological and biochemical parameters of blood was investigated. There was no significant difference between weight gain in rats, receiving compound and control (121±5.10 vs 115±7.2g, respectively). There were no significant changes detected in hematology (red blood cells, 5.63±0.23 vs 4.97±0.17; white blood cells, 12575±170.78 vs 10950±238; platelet, 312500 ± 9574 vs 31000±21602 (cells ml-1)x106; hemoglobin, 13.25±0.3 vs 13.27 ±0.36%, for experimental and control rats, respectively) or blood biochemistry (serum glutamic oxaloacetic transaminase, 11.5±1.29 vs 11.75±1.25IU L-1, serum glutamate pyruvate transaminase, 8.25±1.26 vs 7.25±1.5IU L-1, serum alkaline phosphatase 41.25 ±1.89 vs 44.25 ± 3.3IU L-1. Uric acid, 7.05±0.129 vs 7.3± 0.22; urea, 42.25 ± 1.708 vs 41.5 ± 2.64; creatinine, 0.85±0.05 vs 1.07±0.188mg dL-1, for experimental and control rats, respectively). Therefore, the compound, 4-hydroxy nitrobenzene (300μg day-1) over 14 days, had no toxic effects on rats.

Cited References   |    Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

 
 
 
 
 
 
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility